WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment
Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma. The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat. The study, whose findings appeared in Nature Cancer, sought to test a novel DNA platform that designs a personalized vaccine aimed at preventing glioblastoma tumors from recurring. Glioblastoma grows aggressively and patients rarely survive for more than a year or two after diagnosis, and scientists have been racing to develop new treatments that…
